I-Flow/HAPC
This article was originally published in The Gray Sheet
Executive Summary
Proposed sale price of I-Flow's InfuSystem infusion pump distribution subsidiary is reduced from $140 million to $100 million, plus a $12 million "earn out payment," under a memorandum of intent with purchaser HAPC, the firms announce Sept. 12. The price cut "reflects the realities of today's economic environment and the marketplace," explains I-Flow CEO Donald Earhart. The planned divestiture was announced last September to allow I-Flow to focus on its On-Q pain drug-delivery devices (1"The Gray Sheet" Oct. 9, 2006, p. 11)
You may also be interested in...
I-Flow’s Focus Is On-Q As It Drops Infusion Pump Distribution Unit
I-Flow's divestiture of its infusion pump distribution subsidiary InfuSystem for $140 mil. will help fund clinical trials and market share expansion efforts for its On-Q infusion system, the firm says
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.